MK-677 (Ibutamoren): What the Evidence Shows

MK-677 — sold under the names ibutamoren and ibutamoren mesylate — is one of the few "muscle peptides" that isn't actually a peptide. It is a small, orally active molecule, which is a big part of its appeal: no injections, no reconstitution, just a daily tablet that reliably raises your growth hormone (GH) and IGF-1. In peptide and bodybuilding circles it is marketed for muscle, fat loss, deeper sleep, and "anti-aging."

We'll be direct about the core finding up front, because the marketing skips it: MK-677 does raise the hormones — but the best human trial we have, a full year long, found it raised lean body mass without any measurable gain in muscle strength or physical function. That gap between "the lab marker went up" and "you got stronger or functioned better" is the whole story of this compound. On top of it sit several hard facts: MK-677 was never FDA-approved (its drug development was halted), it is sold as a grey-market research chemical, it is banned in tested sport by WADA, and it carries real metabolic side effects — appetite spikes, fluid retention and edema, raised fasting glucose and insulin resistance, and lethargy.

What MK-677 Actually Is

Most of the compounds in this space — BPC-157, TB-500, ipamorelin — are injectable peptides. MK-677 is different. It is a non-peptide, orally bioavailable ghrelin-receptor agonist (a "ghrelin mimetic"): it activates the growth-hormone secretagogue receptor (GHS-R1a), the same receptor the hunger hormone ghrelin uses¹. By switching on that receptor, MK-677 drives your own pituitary to release more growth hormone in its natural pulses, which in turn raises circulating IGF-1².

This mechanism is genuinely well characterized — it is not folklore. MK-677 came out of a serious drug-development program at Merck in the 1990s aimed at growth-hormone deficiency, frailty, and osteoporosis². Early controlled studies in healthy people established the basic pharmacology cleanly. A 7-day study in healthy young men showed that a single daily oral dose raised 24-hour GH secretion and IGF-1³. In healthy elderly subjects, daily oral MK-677 stimulated the GH/IGF-1 axis back toward levels typical of younger adults⁴. So the headline claim — "MK-677 reliably increases GH and IGF-1, by mouth" — is true and reproducible.

Where it falls apart is the next leap: that raising those two hormones automatically delivers the muscle, performance, and longevity benefits the sellers promise.

What the Evidence Actually Shows

The biomarkers go up — reliably

This is MK-677's one undisputed strength. Across multiple independent studies it consistently raises GH and IGF-1, and it does so orally and durably rather than as a brief spike³⁴. It also nudges related physiology: in healthy and functionally impaired older adults it increased markers of bone turnover⁵, and a prolonged-treatment study reported improved sleep quality, with more slow-wave and REM sleep⁶. There is even a short metabolic finding worth its honesty: when healthy volunteers were put into a catabolic, calorie-restricted state, MK-677 reversed the diet-induced nitrogen wasting — a real anti-catabolic signal⁷. So MK-677 demonstrably moves biology. The question is whether moving it helps.

The one-year trial: lean mass up, strength and function flat

The single most important study on MK-677 is the one the marketing never quotes. In a randomized, double-blind, placebo-controlled trial, Nass and colleagues gave oral MK-677 to healthy older adults for a full year — far longer than almost any peptide study⁸. The result is the honest core of this compound:

• •MK-677 increased lean body mass versus placebo. The hormones did their job.
• •But it produced no significant improvement in muscle strength and no improvement in physical function⁸.

That dissociation matters enormously. A large share of the "lean mass" gain on GH-axis drugs is water and other non-contractile tissue, not functional muscle — which is exactly why the scale and the body-composition scan can move while strength does not. The trial also flagged the metabolic cost: MK-677 increased fasting blood glucose and reduced insulin sensitivity⁸. This is the best-quality, longest human evidence we have, and it says the marker rises but the outcome that actually matters to a lifter or an older adult — being stronger, moving better — did not.

Where it was tested for real disease, it failed the endpoints

MK-677 was studied as an actual drug candidate, and those trials are sobering. In two studies of older patients recovering from hip fracture, MK-0677 (ibutamoren) raised IGF-1 but did not produce the hoped-for clinical recovery benefit — and the larger phase IIb trial was specifically cautious about its use given concerns including congestive heart failure in this frail population⁹¹⁰. In a randomized trial in Alzheimer's disease, MK-677 raised IGF-1 but had no clinical effect on disease progression¹¹. These are not fringe results; they are the reason the development program did not lead to an approved drug. When MK-677 was asked to deliver outcomes rather than biomarkers, it repeatedly came up empty.

The Side-Effect Profile Is Real

MK-677's side effects flow directly from its mechanism, and they are not trivial:

• •Appetite spike. Because it activates the ghrelin (hunger) receptor, MK-677 reliably increases appetite — useful if you are trying to bulk, a liability if you are not, and a confounder for anyone claiming it causes "fat loss"¹.
• •Fluid retention and edema. GH-axis activation causes sodium and water retention. Edema and joint-related complaints are characteristic class effects, and the heart-failure caution raised in the frail hip-fracture population reflects how much that fluid load can matter¹⁰.
• •Raised fasting glucose and insulin resistance. The year-long trial measured this directly: higher fasting glucose and reduced insulin sensitivity⁸. For anyone with prediabetes, diabetes, or metabolic syndrome, this is a meaningful concern, not a footnote.
• •Lethargy and water-weight "bloat." Commonly reported alongside the fluid retention, and consistent with the overall GH-excess picture.

None of this makes MK-677 uniquely dangerous in the short term — but it is not a benign "supplement," and the people most attracted to its IGF-1 boost (older adults, the metabolically vulnerable) are often the ones its side effects hit hardest.

Regulatory & Legal Reality

This is where MK-677 leaves the world of approved medicine entirely.

It was never FDA-approved. Despite a full clinical-development program, MK-677 was never approved by the FDA for any indication, and that development was halted. There is no FDA-approved finished-drug label for ibutamoren — the only DailyMed listings are bulk active-ingredient records from a compounding-chemical supplier, not an approved medicine. Practically, every MK-677 product sold to consumers is an unapproved grey-market "research chemical," typically labeled "not for human consumption," with no FDA oversight of identity, dose, or purity.

It is banned in tested sport. The World Anti-Doping Agency lists ibutamoren (MK-677) by name as a growth-hormone secretagogue under Class S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics, prohibited at all times (in- and out-of-competition). Any tested athlete using it risks a sanction. We cover this across the category in are GH peptides safe and legal?.

How It Compares

MK-677 is constantly compared to the injectable GH-axis peptides, and the comparison is clarifying. The GHRH analogs and ghrelin-receptor peptides like sermorelin, ipamorelin and CJC-1295 work through the same GH/IGF-1 pathway but as injectables — and for a head-to-head on the secretagogue logic, our sister site has a dedicated breakdown of [sermorelin vs MK-677](https://somnipeptide.com/sermorelin-vs-mk-677). The honest throughline across all of them, which we lay out in growth-hormone peptides and recovery, is the same gap MK-677 makes so vivid: these compounds reliably raise the hormones, but proof that the hormone bump becomes real-world strength, recovery, or healthy muscle is thin to absent. If your goal is muscle, see how MK-677 fits the wider, mostly-unproven picture in our guide to peptides for muscle growth. And for the fat-loss flip side of the same story — a GH-derived peptide engineered to burn fat that then failed its pivotal human trial — see our review of AOD-9604 for fat loss and its unmodified cousin HGH Fragment 176-191. The "exercise mimetic" peptide MOTS-c sits in the same evidence bracket: striking rodent endurance data, but no human performance trial to back the marketing.

The Bottom Line

MK-677 (ibutamoren) is the rare GH-axis compound that does exactly what it says on one axis and almost nothing on the other. It is an oral, well-characterized ghrelin-receptor agonist that reliably raises GH and IGF-1 — that part is real and reproducible. But the best human evidence, a year-long randomized trial, found it added lean (largely non-functional) mass without improving strength or physical function, while raising fasting glucose and cutting insulin sensitivity. As an actual drug candidate it failed its clinical endpoints in hip-fracture recovery and Alzheimer's disease, which is why it was never FDA-approved. Add the appetite spike, edema, glucose effects, grey-market sourcing, and WADA S2 ban, and the verdict is straightforward: MK-677 raises the numbers far more convincingly than it changes the outcomes that actually matter. If you want to see how the providers and protocols in this space stack up, we rank them in our guide to the best recovery peptides, and the pillar context lives in our sermorelin athletic-recovery evidence review. And if you're comparing GH-secretagogues like this against the androgen-receptor route, see our honest peptides vs SARMs for recovery and muscle breakdown.